Edwards Lifesciences (NYSE:EW – Get Rating) had its price target hoisted by analysts at Truist Financial  from $86.00 to $93.00 in a report released on Monday, The Fly reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Truist Financial’s target price would suggest a potential upside of 10.25% from the company’s previous close.

Several other analysts have also weighed in on the stock. UBS Group assumed coverage on shares of Edwards Lifesciences in a research report on Tuesday, March 28th. They set a “neutral” rating and a $84.00 target price on the stock. StockNews.com assumed coverage on shares of Edwards Lifesciences in a report on Thursday, March 16th. They set a “hold” rating for the company. Canaccord Genuity Group lifted their price target on shares of Edwards Lifesciences from $68.00 to $76.00 and gave the company a “hold” rating in a report on Wednesday, February 1st. Piper Sandler downgraded shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating and cut their price target for the company from $95.00 to $80.00 in a report on Monday, January 30th. Finally, Wells Fargo & Company downgraded shares of Edwards Lifesciences from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $97.00 to $78.00 in a research note on Wednesday, March 8th. One analyst  has rated the stock with a sell rating, eleven have assigned  a hold rating and eight have assigned  a buy rating to the company. According to MarketBeat.com, the stock  has an average rating of “Hold” and an average price target of $86.95.

NYSE EW opened at $84.35 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.03 and a quick ratio of 2.17. The company’s fifty day moving average is $79.95 and its two-hundred day moving average is $78.26. Edwards Lifesciences has a 52-week low of $67.13 and a 52-week high of $131.10. The firm has a market capitalization of $51.12 billion, a price-to-earnings ratio of 34.57, a P/E/G ratio of 4.91 and a beta of 1.02.

Edwards Lifesciences (NYSE:EW – Get Rating) last issued its earnings results on Tuesday, January 31st. The medical research company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.03. Edwards Lifesciences had a net margin of 28.27% and a return on equity of 26.05%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same period in the previous year, the business earned $0.51 EPS. The firm’s revenue was up 1.5% on a year-over-year basis.  Equities research analysts forecast that  Edwards Lifesciences will post 2.52 EPS for the current year.

In related news, CEO Michael A. Mussallem sold 19,875 shares of the stock in a transaction on Friday, April 14th. The shares were sold at an average price of $84.20, for a total transaction of $1,673,475.00. Following the completion of the transaction, the chief executive officer now owns 60,948 shares in the company, valued at $5,131,821.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 4,000 shares of the stock in a transaction on Wednesday, February 15th. The shares were sold at an average price of $76.01, for a total value of $304,040.00. Following the completion of the sale, the vice president now owns 18,911 shares in the company, valued at $1,437,425.11. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 19,875 shares of the stock in a transaction on Friday, April 14th. The shares were sold at an average price of $84.20, for a total transaction of $1,673,475.00. Following the completion of the sale, the chief executive officer now owns 60,948 shares of the company’s stock, valued at approximately $5,131,821.60. The disclosure for this sale can be found here. Insiders sold 97,821 shares of company stock worth $7,749,733 over the last quarter. 1.29% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. lifted its position in  Edwards Lifesciences by 0.3% during the first quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock valued at $5,127,000 after buying an additional 117 shares during the period.  Geller Advisors LLC increased its holdings in shares of  Edwards Lifesciences by 6.5% during the first quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock valued at $231,000 after acquiring an additional 120 shares in the last quarter.  Allworth Financial LP increased its holdings in shares of  Edwards Lifesciences by 2.5% during the first quarter. Allworth Financial LP now owns 5,015 shares of the medical research company’s stock valued at $415,000 after acquiring an additional 122 shares in the last quarter.  Pacer Advisors Inc. increased its holdings in shares of  Edwards Lifesciences by 1.8% during the third quarter. Pacer Advisors Inc. now owns 7,425 shares of the medical research company’s stock valued at $614,000 after acquiring an additional 134 shares in the last quarter.  Finally, MV Capital Management Inc. increased its holdings in shares of  Edwards Lifesciences by 74.1% during the third quarter. MV Capital Management Inc. now owns 329 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 140 shares in the last quarter. Institutional investors and hedge funds own  80.35% of the company’s stock.

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.